Royalty Report: Drugs, Diagnostic, Biotechnology – Collection: 7118

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • Diagnostic
  • Biotechnology
  • Cancer
  • Diagnostic Substances
  • Disease
  • Therapeutic
  • DNA
  • Veterinary
  • Medical
  • Device
  • Technical Know How
  • Genome
  • Fibrosis

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 7118

License Grant
The Sublicensor is the exclusive Licensee of the Patent Rights  relating to the Field under the 2006 Exclusive License Agreement and is willing to grant the Sublicensee a non-exclusive royalty-bearing SubLicense.
License Property
Patent Rights shall mean Patent Application PCT/lT 2005/000634 filed October 28, 2005 entitled Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof (published as WO 2006/046270), subject to the rights granted by Original Licensor to the Sublicensor pursuant to the Exclusive License Agreement.

Nucleophosmin (NPM1) Gene Mutation Detection in Acute Myeloid Leukemia (NPM1 exon 12)
Indications for Molecular Testing
• Acute Myeloid Leukemia
Testing Methodology
NPM1 mutation detection involves polymerase chain reaction (PCR) followed by capillary electrophoresis separation to detect the most common insertion mutations (4 to 11 nucleotides) in NPM1 exon 12. (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
Interpretation of DNA analysis Nucleophosmin-1 (NPM1) gene codes for a nucleocytoplasmic shuttling protein that plays a key role in cellular processes including ribosome biogenesis, genomic stability, regulation of transcription, and modulation of tumor suppressor gene transcription. NPM1 is the most common genetic abnormality in AML.

Field of Use
The Field is Laboratory Services for testing nucleophosmin protein (NPM1) nucleic acid mutations, including the monitoring of minimal residual disease, in all human sample specimens. For avoidance of doubt, the Field strictly includes molecular testing.

IPSCIO Record ID: 5809

License Grant
The Company entered into a License Agreement wherein it obtained the Exclusive rights for the generic marker for Acute Myeloid Leukemia and intends to utilize these rights for the development of new diagnostic tools.
License Property
The new test is based on a recent discovery that mutations in a nucleophosmin (NPM1) gene are characteristic of 30-40% of the cases of AML. NPM1 is a protein involved in regulation of ribosome biogenesis, cell division, cell death, and other important processes.

Mutations in nucleophosmin NPM1 are the most frequent acquired molecular abnormalities in acute myeloid leukemia (AML).

Field of Use
Xenomics has obtained an exclusive license for the invention and developed a test that detects all 45 known mutations of NPM1 in a single reaction. The results will help physicians with prognosis, therapy, and monitoring of the disease.

IPSCIO Record ID: 7164

License Grant
Licensor is the exclusive licensee of the Patent Rights relating to the Field and is willing to grant to Licensee a royalty-bearing Sublicense in the Territory to use such Patent Rights in the Field on the terms and conditions set forth herein.
License Property
DNA-based biomarker, NPM1, is specific for a subtype of acute myeloid leukemia.

“AML Profiler®” shall mean the Licensor owned dedicated diagnostic microarray based on, for example, the Affymetrix GeneChip platform, as manufactured by Affymetrix (USA), for the detection of several chromosomal aberrations, gene mutations and the expression of relevant prognostic genes in samples from patients with Acute Myeloid Leukemia.

“Patent Rights” shall mean Patent Application PCT/IT2005/000634 filed October 28, 2005 entitled “Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof” (published as WO 2006/046270).

Field of Use
Field shall mean Laboratory Services rendered for the testing, analysis, and interpretation of nucleophosmin (nucleolar phosphoprotein B23 numatrin) mutations as defined by Patent Rights (NPM) in human clinical samples including using the AML Profiler®.

This NPM1 marker provides valuable information and insights as to disease prognosis and monitoring for minimal residual disease. Testing for NPM1 mutations has been added to AML practice guidelines by the National Comprehensive Cancer Network .

IPSCIO Record ID: 7107

License Grant
The Sublicensor hereby grants to  German Sublicnesee, a non-exclusive, royalty-bearing SubLicense under the Patent Rights in the territory in the Field of screening for nucleophosmin protein (NPM1) nucleic acid mutations, including the monitoring of minimal residual disease, in all human sample specimens.
License Property
SubLicense as used herein means a License to use the Patent Rights to make, have made, use, offer to sell, sell and market the Laboratory Services in the Field and in the European Territory, until the patent expires.

Patent Rights shall mean European Patent Application 07021463.0 filed October 28, 2005 entitled Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof (published as 1 944 316 A1), as well as all divisions, re-issues after patent restriction procedures including limitation, opposition and nullification procedures, renewals, time and/or territory extensions of such patent subject to the rights granted by Original Licensor to the Sublicensor pursuant to the Exclusive License Agreement, as limited by this Agreement.

The Licensee shall have no right to further subLicense.

Field of Use
Field shall mean screening for nucleophosmin protein (NPM1) nucleic acid mutations, including the monitoring of minimal residual disease, in all human sample specimens. For avoidance of doubt, the Field strictly includes molecular screening.

IPSCIO Record ID: 7117

License Grant
The Sub-Licensor is the exclusive licensee of the Patent Rights relating to the Field under the Exclusive License Agreement dated May 2006, and is willing to grant to the Sub-Licensee a non-exclusive, royalty-bearing Sublicense in the Territory to use such Patent Rights in the Field.
License Property
The Sub-Licensee shall have no right to further sublicense.

Patent Rights shall mean Patent Application PCT/IT2005/000634 filed October 28, 2005 entitled Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof (published as WO 2006/046270), and foreign equivalents, including Canadian Patent Application 2585965 as well as all continuations, divisions, reissues, reexaminations, renewals, or extensions of such patents subject to the rights granted by Original Licensor pursuant to the Exclusive License Agreement, as limited by this Agreement.

Field of Use
Field shall mean identification and diagnosis, including monitoring of minimal residual disease, of nucleophosmin protein (NPM1) mutations in bone marrow, blood cells, and other cellular specimens. Specifically excluded is testing of urine or any other cell free specimen. The Field specifically includes IVD Laboratory Services testing and use of NPM1 as a drug target.

IPSCIO Record ID: 7177

License Grant
U.S. company hereby grants to Canadian company, subject to all the terms and conditions of this Agreement a non-exclusive, royalty-bearing Sublicense in the Territory in the Field during the Term. Sublicense as used herein means a license to use the Patent Rights to i) make, have made, use, offer to sell, sell and market the Laboratory Services in the Field, and ii) use, develop, practice, commercialize, and otherwise fully exploit the Services. Canadian shall have no right to further sublicense.
License Property
U.S. company is the exclusive licensee of the Patent Rights (as defined below) relating to the Field (as defined below) under an Exclusive License Agreement and is willing to grant to Canadian company a royalty-bearing Sublicense in the Territory to use such Patent Rights in the Field on the terms and conditions set forth herein.

Canadian company shall have no right during the Term to make, have made, offer to sell, sell and market Products in the Field or use Patent Rights in any way for development and commercialization of therapeutic products.

Patent Rights shall mean Patent Application PCT/IT2005/000634 filed October 28, 2005 entitled Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof (published as WO 2006/046270), and foreign equivalents, including Canadian Patent Application 2585965 as well as all continuations, divisions, reissues, reexaminations, renewals, or extensions of such patents subject to the rights granted by Original Licensor to U.S. company pursuant to the Exclusive License Agreement, as limited by this Agreement.

Service shall mean any service or part thereof that when used, commercialized or marketed in the Territory would infringe on any Valid Claim of the Patent Rights absent the Sublicense herein granted. This includes methods used to determine the presence of Nucleophosmin protein (NPM) mutants diagnosis; monitoring of minimal residual disease; prognostic evaluation; monitoring of therapy of acute myeloid leukemia (AML) for commercial testing and for clinical trials.

Field of Use
Field shall mean diagnosis, including monitoring of minimal residual disease, of nucleophosmin protein (NPM1) mutations in bone marrow or blood cells. The Field specifically includes IVD Laboratory Services testing and use of NPM1 as a drug target.

IPSCIO Record ID: 7173

License Grant
The Licensor grants to the Licensee, a non-exclusive, royalty-bearing SubLicense in the territory in the Field of laboratory testing services and products, including without limitation, diagnosis, including monitoring of minimal residual disease, of nucleophosmin protein (NPM1) mutations in bone marrow or blood cells. The Field specifically includes IVD Laboratory Services testing and use of NPM1 as a drug target.
License Property
Patent Rights shall mean Patent Application PCT/IT2005/000634 filed October 28, 2005 entitled Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof (published as WO 2006/046270), and foreign equivalents, including Canadian Patent Application 2585965 as well as all continuations, divisions, reissues, re-examinations, renewals, or extensions of such patents subject to the rights granted by Original Licensor to the Licensor pursuant to the Exclusive License Agreement, as limited by this Agreement.
Field of Use
The field specifically includes IVD Laboratory Services testing and use of NPM1 as a drug target.

IPSCIO Record ID: 4241

License Grant
The Licensor, two individual, entered into a License Agreement with Licensees, wherein it obtained the exclusive rights for the genetic marker for Acute Myeloid Leukemia (AML).
License Property
Additionally, the Company paid $100,000 and issued warrants for the purchase of 100,000 shares of common stock at $1.80 per share as a finder’s fee to an independent third party.
Field of Use
The Licensee intends to utilize these rights for the development of new diagnostic tools.

The Licensee licensed a new DNA-based biomarker (NPM1) specific for a subtype of acute myeloid leukemia (AML); this marker provides valuable information and insights as to disease prognosis and monitoring for minimal residual disease (MRD). Testing for NPM1 mutations has been added to AML practice guidelines by the National Comprehensive Cancer Network (NCCN).

IPSCIO Record ID: 7182

License Grant
The SubLicensor is the exclusive licensee of the Patent Rights  under the Exclusive License Agreement and is willing to grant to a royalty-bearing Sublicense.

The Sublicensor hereby grants to the French SubLicensee, a co-exclusive, royalty-bearing SubLicense to the Patents, in the territory in the Field during the Term.

License Property
The term diagnosis includes Research Use Only, in Vitro Diagnostic and Analyte specific reagent fields.

Patent Rights shall mean Patent Application PCT/IT2005/000634 filed October 28, 2005 entitled Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof (published as WO 2006/046270), and foreign equivalents, as well as all continuations, divisions, reissues, re-examinations, renewals, or extensions of such patents subject to the rights granted by Original Licensor to the SubLicensor pursuant to the Exclusive License Agreement, as limited by this Agreement.

Field of Use
Field shall mean diagnosis, including monitoring of minimal residual disease, of nucleophosmin protein (NPM1) mutations in bone marrow or blood cells. The Field specifically excludes IVD Laboratory Services testing and use of NPM1 as a drug target.

IPSCIO Record ID: 7184

License Grant
The Sub-Licensor is the exclusive licensee of the Patent Rights under the Exclusive License Agreement dated May 2006 and is willing to grant to the Sub-Licensee a royalty-bearing co-exclusive Sublicense in the Territory to use such Patent Rights in the Field.
License Property
Laboratory Services shall mean services performed by reference laboratories in the Territory.

Patent Rights shall mean Patent Application PCT/IT 2005000634 filed October 28, 2005 entitled Nucleophosmin protein (NPM)  mutants, corresponding gene sequences and uses thereof (published as WO 2006/046270), and foreign equivalents, as well as all continuations, divisions, reissues, re-examinations, renewals, or extensions of such patents subject to the rights granted by Original Licensor to the Sub Licensor pursuant to the Exclusive License Agreement, as limited by this Agreement, and any related improvements necessary for Products in the Field.

Field of Use
Field shall mean diagnostic products that assay for nucleophosmin protein (NPM1) mutants, corresponding nucleic acid sequences and uses thereof, including research use only, analyte specific reagent, and in vitro diagnostic products. For the avoidance of doubt, the Field specifically excludes laboratory service testing and therapeutic uses.

IPSCIO Record ID: 7178

License Grant
Licensor, two individuals of Italy, hereby grants to Licensee an exclusive, royalty-bearing license, including the right to grant sublicenses under the Licensed Patent Rights and Licensed Technology in the worldwide territory for all fields of use.
License Property
Licensed Patent Rights
PCT/IT05/000634, filed on October 28, 2005, claiming priority to Italian Patent Application No. RM2004A000534, filed on October 29, 2004.
Field of Use
The invention relates to new nucleophosmin protein (NPM) mutants, corresponding gene sequences and relative uses thereof for diagnosis, monitoring of minimal residual disease; prognostic evaluation and therapy of the acute myeloid leukemia (AML)

IPSCIO Record ID: 2099

License Grant
The Company hereby grants a non-exclusive immunity from suit under PCR Technology solely to use Licensed Technology to perform Licensed Services within the United States and its possessions and the Commonwealth of Puerto Rico; gene amplification process known as the polymerase chain reaction ('PCR') technology (by United States Patent Nos. B1 4,683,195 and B1 4,683,202).
License Property
'Licensed Technology' shall mean the application of PCR Technology.

PCR Technology is used to detect the presence, absence or quantity of a nucleic acid sequence associated with a specific human disease or condition.

Field of Use
Licensed Field shall mean the field of human in vitro diagnostics solely for the detection of genetic diseases, genetic pre-disposition to disease, microorganisms associated with infectious diseases, cancer, or for tissue transplant typing or Parentage.

IPSCIO Record ID: 26464

License Grant
The Licensee was granted the non-exclusive right to polymerase chain reaction technology or 'PCR' to perform the Licensed Services within the United States and its possessions and the Commonwealth of Puerto Rico.

The Licensed Services shall mean the performance of an Assay by BTRL to detect nucleic acid sequences associated with a human disease or condition within the Licensed Field.  Licensed Services include but are not limited to, any combination of the steps of collecting a sample for analysis, isolating nucleic acid sequences therein, amplifying one or more desired sequences, analyzing the amplified material and reporting the results.

License Property
PCR Technology shall mean polymerase chain reaction technology covered by United States Patent Nos. B1 4,683,195 and B1 4,683,202.
Field of Use
The Licensed Field shall mean the field of human in vitro diagnostics solely for the detection of genetic diseases, genetic pre-disposition to disease, microorganisms associated with infectious diseases, cancer, or for tissue transplant typing or Parentage.

IPSCIO Record ID: 605

License Grant
Swiss Licensor grants to Licensee and its Affiliates, a non-exclusive worldwide right and license under the Licensed Patents as follows to perform in vitro human and/or animal diagnostic testing procedures on a sample of material obtained from a human or animal, as applicable, solely to detect the presence, absence or quantity of a nucleic acid sequence associated with a disease or condition in the Licensed Fields.
License Property
Other Technology shall mean the processes covered by the method claims (if they are Valid Claims) of United States Patent Nos. 5,008,182, 5,677,152, 5,773,258 and 5,176,995, and any reissue or reexamination patents thereof, and the claims (if they are Valid Claims) of United States Patent No. 5,110, 920, and any reissue or reexamination patents thereof; and any Valid Claims of the foreign counterparts of the foregoing listed patents or claims.

PCR Technology shall mean polymerase chain reaction technology covered by Valid Claims of United States Patent Nos. B1 4,683,195, B1 4,683,202, and 4,965,188 and any reissue or reexamination patents thereof; and any Valid Claims of the foreign counterparts of the foregoing listed patents or claims.

Quantitation Technology shall mean the method claims (if they are Valid Claims) of United States Patent Nos. 5,389,512 and 5,219,727, and any reissue or reexamination patents thereof, and claims 1-4, 8, 9 and 15-18 (if they are Valid Claims) of United States Patent No. 5, 476,774, and any reissue or reexamination patents thereof; and any Valid Claims of the foreign counterparts of the foregoing listed patents or claims.

RT and RT-PCR  Technology shall mean the reverse transcription process covered by the method claims (if they are Valid Claims) of United States Patent Nos. 5,407,800, 5,310,652, 5,561,058, 5,618,703 and 5,322,770, and any reissue or reexamination patents thereof, and the claims (if they are Valid Claims) of United States Patent No. 5,693,517, and any reissue or reexamination patents thereof; and any Valid Claims of the foreign counterparts of the foregoing listed patents or claims.

'5' Nuclease Technology' shall mean only the processes defined by the method claims (if they are Valid Claims) of United States Patent Nos. 5,210,015 and 5,487,972 and any reissue or reexamination patents thereof and the reaction mixture claims (if they are Valid Claims) of United States Patent No. 5,804,375 and any reissue or reexamination patents thereof; and any Valid Claims of the foreign counterparts of the foregoing listed patents or claims.

Field of Use
Diagnostic Services Field means the field of human in vitro diagnostics for the detection, quantitation, monitoring, genotyping, or phenotyping, of genetic and infectious diseases, disease susceptibility, genetic pre-disposition to disease or cancer; analyzing specimens taken from a human being for the purpose of testing, with respect to that human being, for a physiological or pathological state, for a congenital abnormality, for safety and compatibility of a treatment or to monitor therapeutic measures; or any use of PCR as a testing service to provide to a person data, results or interpretations of any application of PCR for purposes of therapy or diagnosis of a human being, including, without limitation, clinical laboratory services, whether or not a fee is charged for such services; tissue transplant typing, including testing performed on animal tissue intended for use in xenotransplantation; Parentage Determination; diagnosis, disease management; and clinical trials, whether or not a patient result is provided directly or indirectly to a patient.  Licensed Field shall specifically exclude any services performed for screening of blood and/or blood products.

IPSCIO Record ID: 2305

License Grant
Licensor is providing the Company with an exclusive worldwide license to Licensor’s existing and future human genome technologies that are useful for the purposes of development and commercialization of certain of the Company's services, including (i) testing, detection and/or analysis of cancer-predisposing genes; (ii) genetic assessment of risk of an individual to develop cancer; and (iii) testing and analysis for the purposes of cancer management.
License Property
The proprietary technologies include functional gene assay and microsatellite instability technology.  In addition, the Company currently uses conventional gene sequencing to detect gene mutations.  The Company intends to utilize protein truncation methods, Oncor’s proprietary Tri-Amp DNA amplification technology, various gel electrophoresis screening methods and automation to detect genetic mutations.
Field of Use
The Licensee was formed to develop genetic testing and information services for the early detection and management of cancer.  Also engaged in research and development programs and organizational efforts.  The rights granted apply to the healthcare industry.

IPSCIO Record ID: 383575

License Grant
Licensor of Switzerland grants a non-exclusive and non-transferable license, without the right to sublicense, under the Licensed Patents in the Territory with the rights to
—  incorporate Licensed Products into Licensee’s Complete Diagnostic Kits,
—  make, offer to sell and sell such Complete Diagnostic Kits in the Licensed Field, and
—  convey with the sale of such Complete Diagnostic Kits the right to use the Complete Diagnostic Kits under the Licensed Patents in the Licensed Field. Licensee’s right to use Complete Diagnostic Kits includes the right to perform evaluations and validations of Complete Diagnostic Kits, but specifically does not include the right to use Complete Diagnostic Kits for the performance of diagnostic services or testing, except that Licensee may use Complete Diagnostic Kits as End Users.
License Property
Licensor owns or controls certain Licensed Patents relating to chemically modified thermostable DNA polymerases, also known as Hot Start Enzymes, for use in polymerase chain reaction, or PCR, technology.

Licensed Product means a chemically modified thermostable DNA polymerase, the manufacture, use or sale of which is covered by one or more Valid Claims of the Licensed Patents, sold by Licensor, directly or through its distributor, or made and sold by a supplier licensed to make and sell the same.

Complete Diagnostic Kit means a Licensee manufactured and trademarked kit covered by one or more Valid Claims of the Licensed Patents, not covered by any Licensor patents other than the Licensed Patents and dedicated for use for PCR in the Licensed Field, and which Licensee manufactured and trademarked kit is comprised of, at a minimum, the essential active reagents used in the practice of PCR for nucleic acid testing in the Licensed Field. For the avoidance of doubt and for the sake of clarification, ASRs, Analyte Specific Reagents, are not Complete Diagnostic Kits.

U.S. Patent No. 5,677,152 — Issued October 14, 1997 (process and kit claims only) Nucleic Acid Amplification Using a Reversibly Inactivated Thermostable Enzyme

U.S. Patent No. 5,773,258 — Issued June 30, 1998 (process and kit claims only) Nucleic Acid Amplification Using a Reversibly Inactivated Thermostable Enzyme

U.S. Patent No. 6,127,155—Issued October 3, 2000 (reaction mixture claims only) Stabilized Thermostable Nucleic Acid Polymerase Compositions Containing Non-Ionic Polymeric Detergents

Field of Use
The Licensed Field means the field of use consisting of products or processes for the measurement, observation or determination of a disease, disease state or genetic predisposition to a disease, by detecting, quantitating, distinguishing and/or monitoring nucleic acids in samples of material originating from a human being for the medical management for that human being, but excluding
—  human identity testing, and
—  the following human disease targets Hepatitis A Virus, Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus, Human Papilloma Virus and Parvovirus B19; provided, however, that the said exclusions for the Human Papilloma Virus and Parvovirus B19 disease targets shall be limited to 3 years from the Effective Date after which time the Human Papilloma Virus and Parvovirus B19 disease targets shall be included within the Licensed Field subject to the royalty and other terms and conditions of this Agreement.

IPSCIO Record ID: 282819

License Grant
Licensor hereby grants to Licensee a non-exclusive license under the Licensed Patents and Technology to make, have made, use (including use in the performance of services for, by or on behalf of its customers), have used, import, market, and/or sell in the Territory, Products designed and marketed solely for use in the Field of Use.
License Property
Technology, as used in this Agreement, shall mean the information, manufacturing techniques, data, designs or concepts developed by Licensor, covering mutations in the gene for cystic fibrosis and uses thereof as encompassed by the claims of U.S. Patent No. 5,981,178 and U.S. Patent No. 6,001,588 entitled “Introns and Exons of the Cystic Fibrosis Gene and Mutations at Various Positions of the Gene”.

5,981,178 – Methods for screening for mutations at various positions in the introns and exons of the cystic fibrosis gene

6,001,588 – Introns and exons of the cystic fibrosis gene and mutations thereof

Licensed Patent(s) shall mean U.S. Patent No. 5,981,178, U.S. Patent No. 6,001,588 and PCT Patent Application No. PCT/CA91/00009 entitled “Introns and Exons of the Cystic Fibrosis Gene and Mutations at Various Positions of the Gene” and all foreign equivalent patent applications and Patent Cooperation Treaty filings, and all patents issuing therefrom, in which Licensor has or acquires a property interest, the current list of such application. Licensed Patent(s) shall also include any divisional, continuation, reissue, reexamination or extension of the above-described patent applications and resulting patents, along with any extended or restored term, and any confirmation patent, registration patent, or patent of addition.

Field of Use
Field of Use shall refer to the field for which Products may be designed, manufactured, used and/or marketed under this Agreement, and shall mean solely Products to be used for the research of, diagnosis of and screening for the disease cystic fibrosis.
Cystic fibrosis is a hereditary disease that affects the lungs and digestive system. The body produces thick and sticky mucus that can clog the lungs and obstruct the pancreas.

IPSCIO Record ID: 273391

License Grant
Licensor hereby grants to Licensee, subject to all the terms and conditions of this Agreement, a worldwide, nonexclusive right and license (without the right to grant sublicenses) under the Patent Rights to (a) use, offer to sell, sell and practice Diagnostic Services in the Field; (b) make, have made, use, offer to sell, sell and import Licensed Reagents in the Field; and (c) make, have made, use, offer to sell, sell and import Kits in the Field. Notwithstanding the foregoing, Licensor hereby grants to Licensee the worldwide, non-exclusive right to convey to the end-user (purchaser) of FDA (U.S. Food and Drug Administration) Approved Kits manufactured by Licensee the right to perform Diagnostic Services solely in conjunction with the use of FDA Approved Kits manufactured by or on behalf of Licensee (without the right to grant sublicenses).
License Property
Patent Rights shall mean collectively the Gene Patent Rights and the Methodology Patent Rights.

Diagnostic Service(s) shall mean the performance of laboratory-based assays covered in whole or in part by a Valid Claim of the Patent Rights.

Gene Patent Rights shall mean the United States and foreign patents and patent applications relating to the APC (Adenomamus polyposis coli) gene and/or the p53 gene and licensed (with the right to grant sublicenses) to Licensor pursuant to the JHU (Johns Hopkins University) License Agreement together with patents arising therefrom and any extensions, registrations, confirmations, reissues, divisions, continuations or continuations-in-part, re-examinations or renewals thereof, including without limitation the patents and patent applications listed hereto (which may be updated from time to time to include such additional patents and patent application that may arise therefrom); provided, however, that Gene Patent Rights expressly excludes any claims of such patents and patent applications that fall outside of the Field, including, without limitation, claims to antibodies, to the treatment, prevention or remedying of a gene deficiency, to purified proteins, or to DNA (Deoxyribonucleic acid) sequences other than those sequences that correspond to the p53 gene and the APC (Adenomatous polyposis coli) gene; provided further that DNA sequences which are (i) immediately adjacent to the p53 or APC genes and (ii) necessary to the use of the p53 or APC genes, respectively, in the Field shall be considered within the Gene Patent Rights.

US Patent No.  5,352,775 – APC gene and nucleic acid probes derived therefrom
US Patent No.  5,527,676 – Detection of loss of the wild-type P53 gene and kits therefor

Methodology Patent Rights shall mean the United States and foreign patents and patent applications relating to methods of detecting mammalian nucleic acids isolated from stool specimens and reagents therefor and licensed (with the right to grant sublicenses) to Licensor pursuant to the JHU (Johns Hopkins University) License Agreement together with patents resulting therefrom and any extensions, registrations, confirmations, reissues, divisions, continuations or continuations-in-part, re-examinations or renewals thereof, including without limitation the patents and patent application listed hereto (which may be updated from time to time to include such additional patents and patent applications that may arise therefrom).

US Patent Application No. W093/20235 and 08/861,910 (detecting mammalian nucleic acids from stool)

Licensed Reagent shall mean any Reagent covered in whole or in part by a Valid Claim of the Patent Rights.

Kit shall mean a collection of one or more Reagents, including at least one Licensed Reagent, packaged in the form of a kit (including an FDA Approved kit).

Field of Use
Field shall mean (a) stool-based detection of any disease or condition (including pre-cancers, staging and monitoring of the foregoing, and therapeutic response) for research and development, Clinical Laboratory Improvement Amendments (CLIA) testing services (and their foreign equivalents), and FDA Approved Kits; and (b) a screening assay (regardless of other uses to which such assay is put) for colorectal cancer in any type of patient samples, excluding tests solely for staging and/or monitoring of colorectal cancer which do not obsolete or adversely impact such screening assay.

IPSCIO Record ID: 27595

License Grant
The Company obtained a non-exclusive license to manufacture and sell products which are useful in polymerase chain reaction (PCR) process and which enable the user to perform in vitro parentage determination testing procedures.
License Property
The licensed product is a reagent kit manufactured by Licensee containing a thermostable DNA polymerase in combination with all such other reagents, enzymes or materials, whether packaged together or separately, as are necessary to perform a PCR-based assay for Parentage Determination Testing, which is covered by at least one Valid Claim within PCR Technology, and (a) which is marketed for use in Parentage Determination Testing and (b) bears a label as specified in in the agreement, setting forth the license limitations.  Licensor owns and has the right to grant licenses under the corresponding foreign counterpart patents and patent applications describing and claiming nucleic acid amplification techniques, including inter alia, a process known as the PCR process.

IPSCIO Record ID: 210375

License Grant
Pursuant to this License agreement between the Licensee and a Swiss third party, is the right to use a license for intellectual property exclusively licensed to this Licensor by the third party.   A license under the Amplification Patent Rights for automated performance of the PCR Process in the Research Field based on the capacity of thermal cyclers used, and a running-royalty component for each use of the process.  In consideration of Licensees payment of the license issuance fee and of royalties on sales of Licensed Research Products, the Third Party grants to Licensee, in the Territory, limited, nonexclusive rights, without the right to sublicense except to its current Affiliates
a)     Licensee is hereby authorized to sell, strictly under Licensees or it Affiliates own Trademarks, Tradenames and/or label(s), Licensed Research Products with a label conveying to end-user purchasers the running-royalty component of a license under the Amplification Patent Rights to use such Licensed Research Products in or with the PCR Process strictly for such purchasers own internal use in the Research Field in conjunction with a thermal cycler whose use is covered by the up-front fee component, either by payment to Licensor or as purchased, and
b)     Licensee may promote Licensed Research Products for such use in or with the PCR Process in the Research Field.  The up-front component of the PCR license for research must be obtained by the end user in order to have a complete license for the automated performance of the PCR Process.  The up-front component may be purchased from Licensor.  Alternatively, it may be obtained through the purchase of thermal cycler(s) or temperature cycling instrument(s) bearing a valid label conveying to purchasers the up-front  component of the license, that is, an Authorized Thermal Cycler.
License Property
The Authorized Thermal Cycler means a thermal cycler or temperature cycling instrument whose use in automated performance of the PCR Process in the Research Field and Application Fields is covered by the up-front fee component of a PCR Process license.  The up-front component of that license may be purchased from Licensor.  Alternatively, the up-front component of that license may be obtained through the purchase of thermal cycler(s)  or temperature cycling instrument(s) bearing a valid label conveying the up-front PCR Process license component.

The Swiss third party Patented Enzymes licensed herein are
a)  native Taq DNA Polymerase, full length, unmutated
b)  recombinant Taq DNA Polymerase, full length, unmutated
c)  Tth DNA Polymerase, full length, unmutated (native or recombinant)

The Licensed Researched Products are any product, including but not limited to kits, which products consist of or contain a Licensed Product and may include all or some of the following components  buffers, nucleotides, enzymes, or other reagents or materials.

Licensed Application Products are Application Kits for a Licensed Application Field or reagents, components or other materials which are sold in connection with the sale of an Applications Kit for a Licensed Application Field by Invitrogen and which are adapted for or promoted or supported for use by customers in PCR Testing or nucleic acid sequencing, or RT AND RT-PCR in Application Fields.

Field of Use
The Application fields include Forensics and Human Identity Applications, Environmental Testing, Agricultural Plant, Animal Identity Testing and Positive Trait Breeding Applications and Food Testing.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.